王焰增(Wang, Yeng-Tseng)
教授
- 信箱：c00jsw00@kmu.edu.tw
- 分機：2138 #21
- 專長：
- 化學、電腦輔助藥物設計
- 生物巨分子結構學
教學
主負責專業課程
（碩）生物分子模擬
參與大學部專業課程
- 醫學系：生物化學
- 牙醫系：生物化學
- 藥學系：生物化學(含分子生物學)
- 香粧品系：生物化學
- 生物科技學系：生物化學
- 呼吸治療系：生物化學概論
- 護理學系：生物化學概論
研究
| 年度 | 計畫名稱 |
| 114 | 整合深度學習和分子模擬策略尋理性開發靶向茲卡NS2B-NS3蛋白酶之異位調控抑制劑(1/2) |
| 114 | 探討新穎秦皮乙素衍生物(DHOT)的抗口腔癌細胞機制: 抑制遷移/血管新生、促進凋亡/DNA傷害反應、抑制Warburg效應/粒線體功能 |
| 113 | 開發具雙價抗聚乙二醇之三功能抗體(mPEG X PEG X HER2)一步武裝聚乙二醇奈米藥物以提升其活體內結合穩定度及治療效果(3/3) |
| 112 | 開發具雙價抗聚乙二醇之三功能抗體(mPEG X PEG X HER2)一步武裝聚乙二醇奈米藥物以提升其活體內結合穩定度及治療效果(2/3) |
| 112 | 使用分子模擬方法與體外活性實驗方法探究具有Nirmatrelvir, PF-00835231與GC376抗藥性之自然發生突變3C-like SARS-CoV-2 Proteases之結構上結合模式 |
著作
| 出版年月 | 著作名稱 | 作者 |
| Mar.25 | Caffeine as a stabilizer in Novel Hydroxypropyl-β-cyclodextrin/Axitinib Drug-Delivery Systems: A computational study | Yeng-Tseng Wang* and Tun-Chieh Chen |
| Feb.25 | A Dual-Structured Chromogenic Enzyme Platform for a Rapid, Sensitive, Durable, and Precise Gene Expression Analysis | Mu-Shen Chang, Chia-Yi Lee, Yu-Yen Chang, Hsin-Yu Wu, Yeng-Tseng Wang, Hsuan Chao, En-Shuo Liu, Hsin-Kai Huang, Wen-Wei Lin* |
| Nov.24 | In silico validation of allosteric inhibitors targeting Zika virus NS2B-NS3 protease | Yeng-Tseng Wang(王焰增)*, Yuan-Chin Hsieh, and Tin-Yu Wu |
| Sep.24 | Integrating molecular dynamics simulation with small- and wide-angle X-ray scattering to unravel the flexibility, antigen-blocking, and protease-restoring functions in a hindrance-based pro-antibody | Jun Min Liao, Shih-Ting Hong, Yeng-Tseng Wang, Yi-An Cheng, Kai-Wen Ho, Shu-Ing Toh, Orion Shih, U-Ser Jeng, Ping-Chiang Lyu, I-Chen Hu, Ming-Yii Huang, Chin-Yuan Chang*, Tian-Lu Cheng* |
| Apr.24 | Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection | Yi-Jung Huang, Tian-Lu Cheng, Yen-Tseng Wang, Chien-Shu Chen, Yu-Ling Leu, Chih-Shiang Chang, Cheng-Han Ho, Shi-Wei Chao, Chia-Tse Li, Chih-Hung Chuang* |
| Apr-24 | Selective activation of IFNγ-ipilimumab enhances the therapeutic effect and safety of ipilimumab | Yi-Jung Huang, Kai-Wen Ho, Tian-Lu Cheng, Yen-Tseng Wang, Shi-Wei Chao, Bo-Cheng Huang, Yu-Shu Chao, Chia-Yu Lin, Yun-Han Hsu, Fang-Ming Chen, Chih-Hung Chuang* |
| Jan-24 | RNF43 Inactivation Enhances the B-RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells | Shih-Han Hsu, Ya-Li Tsai, Yeng-Tseng Wang(王焰增), Che-Hung Shen, Yu-Hsuan Hung, Li-Tzong Chen, Wen-Chun Hung(洪文俊)* |
| May-23 | Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication | 林文瑋, 黃奕中, 王焰增, 林昀萱, 賴凱洛, 陳建樹, 鄭添祿, 張誌祥, 呂玉玲, 陳巧雲**, 莊智弘** |
| Sep-22 | Structural Insights Into Nirmatrelvir (PF-07321332)–3C-like SARS-CoV-2 Protease Complexation: A Ligand Gaussian Accelerated Molecular Dynamics Study | Yeng-Tseng Wang*, Jun-min Liao, Wen-Wei Lin, Chia-Ching Li , Bo-Cheng Huang, Tian-Lu Cheng and Tun-Chieh Chen |
| Jan-22 | A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies | Yuan-Chin Hsieh, Jun-min Liao, Kuo-Hsiang Chuang, Kai-Wen Ho, Shih-Ting Hong, Hui-Ju Liu, Bo-Cheng Huang, I-Ju Chen, Yen-Ling Liu, Jaw-Yuan Wang, Hsiang-Lin Tsai, Yu-Cheng Su, Yen-Tseng Wang* & Tian-Lu Cheng* |